Zachary S Zumsteg

List of Publications by Year
in descending order

98 papers	4,471 citations	136740 32 h-index	114278 63 g-index
98 all docs	98 docs citations	98 times ranked	6374 citing authors

#	Article	IF	Citations
1	Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis. Cancer Medicine, 2017, 6, 2918-2931.	1.3	400
2	A New Risk Classification System for Therapeutic Decision Making with Intermediate-risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation Therapy. European Urology, 2013, 64, 895-902.	0.9	334
3	Association of Black Race With Prostate Cancerâ€“Specific and Other-Cause Mortality. JAMA Oncology, 2019, 5, 975.	3.4	288
4	Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. International Journal of Radiation Oncology Biology Physics, 2019, 104, 778-789.	0.4	247
5	Metastatic Lymph Node Burden and Survival in Oral Cavity Cancer. Journal of Clinical Oncology, 2017, 35, 3601-3609.	0.8	191
6	Metformin and Prostate Cancer: Reduced Development of Castration-resistant Disease and Prostate Cancer Mortality. European Urology, 2013, 63, 709-716.	0.9	152
7	The Natural History and Predictors of Outcome Following Biochemical Relapse in the Dose Escalation Era for Prostate Cancer Patients Undergoing Definitive External Beam Radiotherapy. European Urology, 2015, 67, 1009-1016.	0.9	147
8	Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques. JAMA Oncology, 2017, 3, 1487.	3.4	146
9	Evolution of the Oropharynx Cancer Epidemic in the United States: Moderation of Increasing Incidence in Younger Individuals and Shift in the Burden to Older Individuals. Journal of Clinical Oncology, 2019, 37, 1538-1546.	0.8	127
10	Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer. Annals of Surgical Oncology, 2013, 20, 3469-3476.	0.7	125
11	Comparison of highâ€dose (86.4â€‰<scp>G</scp>y) <scp>IMRT</scp> vs combined brachytherapy plus <scp>IMRT</scp> for intermediateâ€risk prostate cancer. BJU International, 2014, 114, 360-367.	1.3	125
12	Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy. Cancer Cell, 2021, 39, 1202-1213.e6.	7.7	124
13	Incidence of Oropharyngeal Cancer Among Elderly Patients in the United States. JAMA Oncology, 2016, 2, 1617.	3.4	114
14	Treatment at highâ€volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer. Cancer, 2017, 123, 3933-3942.	2.0	108
15	Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer. Journal of Urology, 2015, 194, 1624-1630.	0.2	93
16	Association of Quantitative Metastatic Lymph Node Burden With Survival in Hypopharyngeal and Laryngeal Cancer. JAMA Oncology, 2018, 4, 985.	3.4	82
17	Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. Journal of Urology, 2017, 197, 662-668.	0.2	76
18	Taselisib (GDC-0032), a Potent Î²-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing ActivatingPIK3CAAlterations. Clinical Cancer Research, 2016, 22, 2009-2019.	3.2	70

#	Article	IF	Citations
19	Quantitative survival impact of composite treatment delays in head and neck cancer. Cancer, 2018, 124, 3154-3162.	2.0	68
20	Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. European Urology, 2017, 71, 37-43.	0.9	64
21	Translational and clinical implications of the genetic landscape of prostate cancer. Nature Reviews Clinical Oncology, 2016, 13, 597-610.	12.5	63
22	Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?. Lancet Oncology, The, 2012, 13, e259-e269.	5.1	58
23	Incidence and Mortality Risk Spectrum Across Aggressive Variants of Papillary Thyroid Carcinoma. JAMA Oncology, 2020, 6, 706.	3.4	58
24	Short-term Androgen-Deprivation Therapy Improves Prostate Cancer-Specific Mortality in Intermediate-Risk Prostate Cancer Patients Undergoing Dose-Escalated External Beam Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1012-1017.	0.4	55
25	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. European Urology, 2018, 73, 156-165.	0.9	55
26	Carotid sparing intensity-modulated radiation therapy achieves comparable locoregional control to conventional radiotherapy in T1-2N0 laryngeal carcinoma. Oral Oncology, 2015, 51, 716-723.	0.8	52
27	Interplay and cooperation between SREBF1 and master transcription factors regulate lipid metabolism and tumor-promoting pathways in squamous cancer. Nature Communications, 2021, 12, 4362.	5.8	50
28	Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy. Cancer Cytopathology, 2016, 124, 722-728.	1.4	45
29	The Older Adult With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: Knowledge Gaps and Future Direction in Assessment and Treatment. International Journal of Radiation Oncology Biology Physics, 2017, 98, 868-883.	0.4	45
30	Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma. Journal of Neuro-Oncology, 2014, 116, 357-363.	1.4	39
31	Facility Volume and Survival in Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 408-417.	0.4	37
32	Comparison of Survival After Transoral Robotic Surgery vs Nonrobotic Surgery in Patients With Early-Stage Oropharyngeal Squamous Cell Carcinoma. JAMA Oncology, 2020, 6, 1555.	3.4	36
33	Unification of favourable intermediateâ€, unfavourable intermediateâ€, and very highâ€risk stratification criteria for prostate cancer. BJU International, 2017, 120, E87-E95.	1.3	34
34	Development of a novel salivary gland cancer lymph node staging system. Cancer, 2018, 124, 3171-3180.	2.0	33
35	Human papillomavirusâ€“associated oropharyngeal cancer among patients aged 70 and older: Dramatically increased prevalence and clinical implications. European Journal of Cancer, 2018, 103, 195-204.	1.3	30
36	Effect of Androgen Deprivation on Long-term Outcomes of Intermediate-Risk Prostate Cancer Stratified as Favorable or Unfavorable. JAMA Network Open, 2020, 3, e2015083.	2.8	30

#	Article	IF	Citations
37	Predictors of survival in head and neck mucosal melanoma. Oral Oncology, 2017, 73, 36-42.	0.8	26
38	Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. Journal of Clinical Oncology, 2020, 38, 3024-3031.	0.8	26
39	Improved survival in women versus men with merkel cell carcinoma. Journal of the American Academy of Dermatology, 2021, 84, 321-329.	0.6	26
40	Mortality Risk of Nonoperative Papillary Thyroid Carcinoma: A Corollary for Active Surveillance. Thyroid, 2019, 29, 1409-1417.	2.4	25
41	Erectile function after stereotactic body radiotherapy for localized prostate cancer. BJU International, 2018, 121, 61-68.	1.3	24
42	Parallels Between Low-Risk Prostate Cancer and Thyroid Cancer. JAMA Oncology, 2019, 5, 556.	3.4	24
43	Combined highâ€intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base. Cancer, 2017, 123, 4583-4593.	2.0	23
44	A snapshot of the evolving epidemiology of oropharynx cancers. Cancer, 2018, 124, 2893-2896.	2.0	23
45	Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis. Breast Cancer Research and Treatment, 2013, 139, 497-506.	1.1	22
46	Oral and dental health in head and neck cancer survivors. Cancers of the Head & Neck, 2016, 1, 14.	6.2	22
47	Number of Unfavorable Intermediateâ€Risk Factors Predicts Pathologic Upstaging and Prostate Cancerâ€Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database. Prostate, 2017, 77, 154-163.	1.2	22
48	Antagonizing CD105 enhances radiation sensitivity in prostate cancer. Oncogene, 2018, 37, 4385-4397.	2.6	21
49	The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensityâ€modulated radiotherapy era. Cancer, 2017, 123, 1345-1353.	2.0	20
50	Quantitative lymph node burden as a â€˜very-high-riskâ€™ factor identifying head and neck cancer patients benefiting from postoperative chemoradiation. Annals of Oncology, 2019, 30, 76-84.	0.6	20
51	Survival Impact of Adjuvant Therapy in Salivary Gland Cancers following Resection and Neck Dissection. Otolaryngology - Head and Neck Surgery, 2019, 160, 1048-1057.	1.1	18
52	International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy. Journal of Urology, 2019, 201, 284-291.	0.2	18
53	Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma. Journal of the American Academy of Dermatology, 2021, 84, 312-320.	0.6	17
54	Improved Survival with Surgery in Prostate Cancer Patients Without Medical Comorbidity: A Self-fulfilling Prophecy?. European Urology, 2013, 64, 381-383.	0.9	16

#	Article	IF	Citations
55	The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 523-531.	0.4	16
56	Postoperative chemoradiotherapy in patients with head and neck cancer aged 70 or older with positive margins or extranodal extension and the influence of nodal classification. Head and Neck, 2018, 40, 1228-1236.	0.9	15
57	Predictors of multidomain decline in healthâ€related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. Cancer, 2017, 123, 1635-1642.	2.0	14
58	Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601. Journal of Clinical Oncology, 2022, 40, 3172-3179.	0.8	14
59	Impact of concomitant chemoradiation on survival for patients with T1â€2N1 head and neck cancer. Cancer, 2017, 123, 1555-1565.	2.0	12
60	Natural history of â€˜secondâ€™ biochemical failure after salvage radiation therapy for prostate cancer: a multiâ€institution study. BJU International, 2018, 121, 365-372.	1.3	12
61	Incidental parathyroidectomy in thyroidectomy and central neck dissection. Surgery, 2021, 169, 1145-1151.	1.0	12
62	Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy. Prostate, 2015, 75, 175-182.	1.2	11
63	Anatomical patterns of recurrence following biochemical relapse after postâ€prostatectomy salvage radiation therapy: a multiâ€institutional study. BJU International, 2017, 120, 351-357.	1.3	10
64	Stage I HPVâ€positive oropharyngeal cancer: Should all patients receive similar treatments?. Cancer, 2020, 126, 58-66.	2.0	10
65	Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. Molecular and Cellular Oncology, 2014, 1, e963447.	0.3	9
66	Impact of Flap Reconstruction on Radiotoxicity After Salvage Surgery and Reirradiation for Recurrent Head and Neck Cancer. Annals of Surgical Oncology, 2016, 23, 850-857.	0.7	9
67	Impact of insurance on survival in patientsÂ<Â65 with head & neck cancer treated with radiotherapy. Clinical Otolaryngology, 2020, 45, 63-72.	0.6	9
68	Prognostic Impact of Histologic Grade for Papillary Thyroid Carcinoma. Annals of Surgical Oncology, 2021, 28, 1731-1739.	0.7	9
69	Complete and Sustained Remission of Metastatic Cutaneous Squamous Cell Carcinoma in a Liver Transplant Patient Treated With Talimogene Laherparepvec. Dermatologic Surgery, 2021, 47, 820-822.	0.4	9
70	Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. Prostate, 2017, 77, 1592-1600.	1.2	8
71	Nodal staging convergence for HPVâ^’ and HPV+ oropharyngeal carcinoma. Cancer, 2021, 127, 1590-1597.	2.0	8
72	Predictive impact of metastatic lymph node burden on distant metastasis across papillary thyroid cancer variants. Thyroid, 2021, 31, 1549-1557.	2.4	8

#	Article	IF	Citations
73	Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy. Journal of Clinical Oncology, 2016, 34, 3829-3833.	0.8	7
74	Variations in the association of grade with survival across the head and neck cancer landscape. Head and Neck, 2021, 43, 1105-1115.	0.9	7
75	Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancerâ€“specific Mortality: Competition Between Age and Time to Biochemical Failure. European Urology Oncology, 2018, 1, 276-282.	2.6	6
76	The association between facility volume and overall survival in patients with Merkel cell carcinoma. Journal of Surgical Oncology, 2020, 122, 254-262.	0.8	6
77	Nodal Metastasis Count and Oncologic Outcomes in Head and Neck Cancer: A Secondary Analysis of NRG/RTOG 9501, NRG/RTOG 0234, and EORTC 22931. International Journal of Radiation Oncology Biology Physics, 2022, 113, 787-795.	0.4	6
78	Mucinous Carcinoma with Neuroendocrine Differentiation of Salivary Gland Origin. Head and Neck Pathology, 2017, 11, 249-255.	1.3	5
79	Survival outcomes with concomitant chemoradiotherapy in older adults with oropharyngeal carcinoma in an era of increasing human papillomavirus (HPV) prevalence. Oral Oncology, 2019, 99, 104472.	0.8	5
80	Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics. Oncology, 2021, 35, 119-125.	0.4	5
81	Development and Validation of an Improved Pathological Nodal Staging System for Urothelial Carcinoma of the Bladder. European Urology Oncology, 2019, 2, 656-663.	2.6	4
82	Precision Medicine for Localized Prostate Cancer: Time to Move Beyond NCCN Risk Stratification?. International Journal of Radiation Oncology Biology Physics, 2019, 103, 92-94.	0.4	4
83	Development and Validation of an Improved Pathological Nodal Staging System in Men With Prostate Cancer. Journal of Urology, 2021, , 101097JU0000000000002256.	0.2	4
84	Financial Hardship in Patients With Head and Neck Cancer. JCO Oncology Practice, 2022, 18, e925-e937.	1.4	4
85	Quantitative Nodal Burden and Mortality Across Solid Cancers. Journal of the National Cancer Institute, 2022, 114, 1003-1011.	3.0	4
86	Lifestyle and sociodemographic factors associated with treatment choice of clinically localized prostate cancer in an equal access healthcare system. Prostate Cancer and Prostatic Diseases, 2022, 25, 593-595.	2.0	3
87	Radiation Therapy for the Head and Neck Patient: Advances, Challenges, and Perspectives. Cancer Treatment and Research, 2018, 174, 145-162.	0.2	2
88	The role of concomitant chemoradiotherapy in AJCC 7th edition T1-2N1 oropharyngeal carcinoma in the human papillomavirus era. Oral Oncology, 2020, 110, 104882.	0.8	2
89	Proton Radiation Therapy for Local Control in a Case of Osteosarcoma of the Neck. International Journal of Particle Therapy, 2016, 3, 421-428.	0.9	2
90	Mucosa-associated lymphoid tissue lymphoma of the breast: bilateral metachronous presentation. Leukemia and Lymphoma, 2010, 51, 168-170.	0.6	1

#	Article	IF	Citations
91	Use of Bladder Sparing Surgery for Muscle Invasive Bladder Cancer by Life Expectancy at Diagnosis. Urology Practice, 2021, 8, 94-99.	0.2	1
92	Factors predictive of 90â€day mortality after surgical resection for oral cavity cancer: Development of a recursive partitioning analysis for risk stratification. Head and Neck, 2021, 43, 2731-2739.	0.9	1
93	Development and Validation of a Modified Pathologic Nodal Classification System for Cutaneous Melanoma. JAMA Surgery, 2021, 156, e214298.	2.2	1
94	Personalization of Treatment Intensity for Intermediate-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 112, 744-746.	0.4	1
95	Local versus systemic treatment intensification: what is the optimal strategy for localized prostate cancer?. Prostate Cancer and Prostatic Diseases, 2022, , .	2.0	1
96	ASO Author Reflections: Revisiting the Prognostic Significance of Grade in Papillary Thyroid Carcinoma. Annals of Surgical Oncology, 2020, 27, 852-853.	0.7	0
97	Balancing Risks and Benefits: Treat Bilateral Necks, But Omit the Tongue. International Journal of Radiation Oncology Biology Physics, 2020, 106, 902.	0.4	0
98	Simultaneous Integrated Micro-boost: Reigniting the FLAME for Dose Escalation in Prostate Cancer?. European Urology, 2022, , .	0.9	0